Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.

[1]  Ji Luo,et al.  Regression analysis of case II interval-censored data with auxiliary covariates , 2020 .

[2]  C. Wijbrandts,et al.  Prediction of Response to Targeted Treatment in Rheumatoid Arthritis , 2017, Mayo Clinic proceedings.

[3]  T. Luft,et al.  Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS Cohort , 2016 .

[4]  Ryan Ramanujam,et al.  Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis , 2016, PloS one.

[5]  M. Deehan,et al.  Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance , 2016, Journal of immunology research.

[6]  Ivana Knezevic,et al.  Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. , 2015, Biologicals : journal of the International Association of Biological Standardization.

[7]  E. Havrdová,et al.  Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium , 2015, Clinical and experimental immunology.

[8]  W. Dixon,et al.  Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[9]  K. Bendtzen.  Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence , 2015, Front. Immunol..

[10]  Jesper Tegnér,et al.  Accelerating Translational Research by Clinically Driven Development of an Informatics Platform–A Case Study , 2014, PloS one.

[11]  T. Olsson,et al.  Smokers run increased risk of developing anti-natalizumab antibodies , 2014, Multiple sclerosis.

[12]  T. Olsson,et al.  Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a , 2014, Multiple sclerosis.

[13]  W. Hung,et al.  Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[14]  H. Olsson,et al.  Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab , 2013, Annals of the rheumatic diseases.

[15]  A. Barton,et al.  The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases , 2013, Rheumatology.

[16]  J. Gómez-Reino,et al.  Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. , 2013, JAMA internal medicine.

[17]  C. Allaart,et al.  A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study , 2013, Annals of the rheumatic diseases.

[18]  J. Tegnér,et al.  Implementation of the CDC translational informatics platform - from genetic variants to the national Swedish Rheumatology Quality Register , 2013, Journal of Translational Medicine.

[19]  M. Boers,et al.  Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. , 2012, Arthritis and rheumatism.

[20]  X. Mariette,et al.  Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective , 2012, Annals of the rheumatic diseases.

[21]  Theo Rispens,et al.  Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization , 2012 .

[22]  M. Nurmohamed,et al.  Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner , 2012, Annals of the rheumatic diseases.

[23]  E. Martı́n-Mola,et al.  Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. , 2011, Rheumatology.

[24]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[25]  B. Dijkmans,et al.  The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept , 2010, Annals of the rheumatic diseases.

[26]  Pamela A Shaw,et al.  Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package. , 2010, Journal of statistical software.

[27]  K. Bendtzen,et al.  Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta , 2010, Journal of Neurology.

[28]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[29]  J. Sluiter,et al.  Improvement of Work Ability, Quality of Life, and Fatigue in Patients With Rheumatoid Arthritis Treated With Adalimumab , 2010, Journal of occupational and environmental medicine.

[30]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[31]  Y. Shoenfeld,et al.  Effects of tobacco smoke on immunity, inflammation and autoimmunity. , 2010, Journal of autoimmunity.

[32]  A. Matucci,et al.  Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.

[33]  B. Dijkmans,et al.  Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study , 2009, Annals of the rheumatic diseases.

[34]  D. Sugiyama,et al.  Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies , 2009, Annals of the rheumatic diseases.

[35]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[36]  B. Dijkmans,et al.  The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium , 2007, Annals of the rheumatic diseases.

[37]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[38]  M. Dougados,et al.  The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. , 2007, Joint, bone, spine : revue du rhumatisme.

[39]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[40]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[41]  L. Aarden,et al.  Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[42]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[43]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[44]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[45]  W Pan,et al.  A Multiple Imputation Approach to Cox Regression with Interval‐Censored Data , 2000, Biometrics.

[46]  J C Lindsey,et al.  Tutorial in biostatistics methods for interval-censored data. , 1998, Statistics in medicine.

[47]  J Sun,et al.  A non-parametric test for interval-censored failure time data with application to AIDS studies. , 1996, Statistics in medicine.

[48]  A. Gallant,et al.  Semi-nonparametric Maximum Likelihood Estimation , 1987 .

[49]  B. Turnbull.  The Empirical Distribution Function with Arbitrarily Grouped, Censored, and Truncated Data , 1976 .

[50]  T. Luft,et al.  Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS Cohort. , 2016, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[51]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[52]  S. Wedrén,et al.  Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. , 2011, Arthritis and rheumatism.

[53]  I. Christensen,et al.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. , 2010, Arthritis and rheumatism.

[54]  J J Anderson,et al.  Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. , 2000, Arthritis and rheumatism.

[55]  K M Leung,et al.  Censoring issues in survival analysis. , 1997, Annual review of public health.

[56]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[57]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.